<DOC>
	<DOCNO>NCT00194922</DOCNO>
	<brief_summary>The purpose study determine tolerance efficacy probiotic E. Coli Strain M17 symptom Quality Life Individuals Irritable Bowel Syndrome ( IBS ) .</brief_summary>
	<brief_title>Study Determine Effectiveness Probiotic E. Coli Strain M17 Treating Irritable Bowel Syndrome ( IBS )</brief_title>
	<detailed_description>IBS characterize abdominal discomfort alter bowel function , without identifiable structural biochemical abnormality . Current management approach satisfactory many individual , continue intermittent constipation diarrhea , associate abdominal discomfort . Probiotics , `` friendly bacteria '' , name give new category product show promise managing symptom IBS . In intestine believe compete bacteria , product substance interfere bacteria , improve function mucous line immune function gastrointestinal tract . A common source probiotic culture dairy product , yogurt cheese . E. coli Strain M17 regulate vy Food Drug Administration . It consider health food supplement . E. coli strain M17 identify Russia 70 year ago . It become widely use country former Soviet Union variety gastrointestinal problem , include IBS , inflammatory bowel disease ( ulcerative colitis Crohn 's disease ) , diarrhea , include infant child . It continue produce marketed government control Russian Federation . E. coli strain M17 bring Israel early 1990 's two Russian scientist . It develop human use animal feed approve use Israeli health authority . A special liquid formulation develop sell nutritional supplement pharmacy Israel 2002 product acquire U.S. company , BioBalance Corporation , purpose introduce outside Israel medical food nutritional supplement U.S. country . The purpose research study compare tolerability effectiveness E. coli strain M17 placebo treatment Irritable Bowel Syndrome ( IBS ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Age =18 =80 , males female . Diagnosed IBS Rome II criterion , also call `` bloating '' Normal colonic anatomy past 5 year evidence colonoscopy , flex sigmoidoscopy , Barium enema , Sonography , exam deem acceptable study physician Normal thyroid function test ( compensate thyroid replacement ) negative antibody screen test celiac disease . Normal blood chemistry CBC age , sex measure within 6 month start study . Pregnant , breastfeeding , use approve method contraception ( childbearing potential ) Unstable medical disorder GI disorder ( per discretion screen physician ) , especially Crohn 's disease , history carcinoma bowel , malabsorption syndrome , intolerance certain food type ( lactose ) , functional diarrhea , functional constipation Patient undergone MAJOR abdominal surgery past ( note : appendectomy , example , include definition . Patient E. coli strain M17 administer past six month History major psychiatric disorder substance abuse within previous 2 year , include psychiatric illness require medication may cause doubt validity sign Informed Consent form Existing illness medical condition prevent patient participate study ( severe heart disease , insulin dependent diabetes , hyperactive thyroid gland , HIV positive , anemia , etc . ) Participation another clinical study past four week . Candidate available next 18 week ( 2 week runin , 12 week study , 4 week followup ) Recent abnormal value routine lab test prior begin trial product , value deviate normal either direction factor 2.5 , unless follow test show normal . Elevated liver function test : aspartate aminotransferase alanine aminotransferase &gt; 2.5 time upper limit normal . Elevated renal function test : serum creatinine &gt; 152.4 mmol/L ( appropriate upper cutoff per lab . Abnormal CBC indicate anemia age sex standard . Abnormal urinalysis ( evidence infection albumin ) . Hyperthyroidism hypothyroidism : T4 TSH great less normal range . If previously diagnose , disease must manage stable . Positive antibody test celiac disease . Nonskin malignancy previous 5 year Any use investigational drug within 30 day screen period Any use probiotic supplement within 30 day screen period ( exception standard food yogurt product ) Any use antibiotic within 42 day screen period ( however , candidate may wait initiate screen exam 42 day lapse since antibiotic course complete ) Current use drug treatment study physician believe cause gastrointestinal symptom may confuse add symptom IBS .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>